Manufacturing: Page 16
-
Lonza to separate out specialty ingredients business
As part of the restructuring, Lonza is considering about 130 job cuts, including 50 in Switzerland and 35 in the U.S.
By Kristin Jensen • June 6, 2019 -
Aldevron to build out 14-acre gene therapy campus
New buildings at an existing site in North Dakota will be capable of making $1 billion worth of biologic products each year — according to the company, at least.
By Kristin Jensen • June 6, 2019 -
PE firm nabs Vibalogics, banking on demand for complex viral products
The deal brings 50 employees and a 27,000-square-foot manufacturing facility in Germany under the ownership of Ampersand Capital Partners.
By Jacob Bell • May 30, 2019 -
Kendall Davis/BioPharma Dive
Iovance to invest $75M in cell therapy plant
A new site in Philadelphia, when complete, will be used to produce Iovance's tumor-infiltrating lymphocyte therapies.
By Kristin Jensen • May 29, 2019 -
Sponsored by Lonza
Biologics license application submission: finding expert help
How finding the right partner to provide expert help can move a company further along the drug-development journey.
May 28, 2019 -
Elizabeth Regan/BioPharma Dive
Evotec to buy Just Biotherapeutics for up to $90M
The purchase offers Germany-based Evotec some new technology as well as a stronger foothold for U.S. growth.
By Kristin Jensen • May 23, 2019 -
WuXi Biologics building dedicated facility to supply 'global vaccine leader'
Though the Chinese company didn't name its latest partner, it did say the pair have in place a 20-year manufacturing contract worth more than $3 billion.
By Kristin Jensen • May 23, 2019 -
Yujin Kim/BioPharma Dive
Could Novartis' gene therapy have more than one price?
Indication-based pricing may be possible for less severe patients, who would receive a smaller dose. Lower manufacturing costs would lessen the blow to Novartis too.
By Jonathan Gardner • May 23, 2019 -
Sponsored by Lonza
How to go fast to IND: 3 tips to combine speed with quality
A survey of small-biopharma leaders on their plans and concerns for developing their molecules shows three issues of highest importance: getting their drugs to the clinic quickly, finding expert help and having adequate funding.
May 17, 2019 -
B. Braun invests $1B in IV fluid manufacturing to alleviate shortages
Weather events like Hurricane Maria have fueled an IV solution shortage B. Braun hopes to address by opening, updating and expanding production sites.
By David Lim • May 16, 2019 -
FDA highlights manufacturing quality efforts after recalls, regulatory criticism
An agency report found the industry's average inspection score didn't change much over the last two years, though there remain concerns about quality control in China and India.
By Kristin Jensen • May 16, 2019 -
Thermo Fisher to buy GSK drug plant in Ireland
GSK will receive about $100 million from Thermo for the site, which makes API for drugs that treat conditions like depression and Parkinson's disease.
By Kristin Jensen • May 16, 2019 -
Chemical suppliers take hits from both sides of the trade war
Chemicals produced in the U.S. suffer from higher cost of materials imported from China and the shrinking Chinese export market due to retaliatory tariffs.
By Emma Cosgrove • May 16, 2019 -
Bayer pumping $150M more into biologics
A new facility will focus on large-molecule therapies for oncology, cardiology and additional specialty care areas.
By Jacob Bell • May 13, 2019 -
Catalent, hindered by Softgel weakness, sees stronger growth ahead
Revenues from January to March fell 2% year over year, as the CDMO works through an ibuprofen supply shortage and an accounting change.
By Ned Pagliarulo • May 9, 2019 -
Charles River sees minimal financial impact from cybersecurity breach
An incident disclosed last week likely won't result in significant costs, the company told investors.
By Kristin Jensen • May 9, 2019 -
Renewable energy to power all Novo drug production by next year
The Danish drugmaker set out in 2015 with an ambitious goal to use only electricity generated from renewable sources in its production plants.
By Ned Pagliarulo • May 2, 2019 -
FDA rejects Heron, Nabriva drug applications, citing manufacturing concerns
Both biotechs expected approval of their respective pain and anti-infective drugs, but wound up with disappointment and delays.
By Andrew Dunn • May 2, 2019 -
Amid outbreaks, Merck ramps up measles vaccine manufacturing
The move should maintain availability and provide a greater stateside supply of the company's measles, mumps and rubella vaccine.
By Jacob Bell • May 2, 2019 -
Merck plans to shed facilities, cut jobs in restructuring
A planned restructuring of Merck's manufacturing and supply network will likely cost between $800 million to $1.2 billion in total, the company said.
By Kristin Jensen • May 1, 2019 -
Gilead to build manufacturing site in Maryland to boost cell therapy
The Kite Pharma unit is expanding a production network that includes facilities in California and the Netherlands.
By Kristin Jensen • April 25, 2019 -
GSK to invest $100M in Montana vaccine manufacturing site
The pharmaceutical giant looks to expand capacity for adjuvant systems, including for its high-demand shingles vaccines.
By Kristin Jensen • April 24, 2019 -
Lilly selling antibiotic rights, manufacturing plant in China
As with other big pharmas, antibiotics have become less of a priority for Lilly despite global concerns over the need for new treatments.
By Jacob Bell • April 23, 2019 -
Hospital-led generic drugmaker Civica Rx opens HQ in Utah
Civica is trying to fill a need created by what its leaders see as failures in the market for supplying lower-cost copycat drugs.
By Les Masterson • April 22, 2019 -
'Bubble boy' gene therapy results shoot Mustang Bio's stock up 200%
Following the clinical success, BioPharma Dive spoke with Mustang's CEO on the manufacturing hurdles still standing in the therapy's way.
By Andrew Dunn • April 18, 2019
Previous
